Systematische Darstellung epidemiologischer Kenngrößen der häufigsten ICCC-3 Diagnosen / Systematic Presentation of Descriptive Measures for Frequent ICCC-3 Diagnoses

	Seite / Page
All malignancies	11
I Leukaemias, myeloproliferative and myelodysplastic diseases	12
I (a) Lymphoid leukaemias	13
I (a) 1 Precursor cell leukaemias	14
I (a) 2 Mature B-cell leukaemias	14
I (b) Acute myeloid leukaemias	15
I (c) Chronic myeloproliferative diseases	16
I (d) Myelodysplastic syndrome and other myeloproliferative diseases	17
II Lymphomas and reticuloendothelial neoplasms	18
II (a) Hodgkin lymphomas	19
II (b) Non-Hodgkin lymphomas	20
II (b) 1 Precursor cell lymphomas	21
II (b) 2 Mature B-cell lymphomas, except Burkitt lymphoma	21
II (b) 3 Mature T-cell and NK-cell lymphomas	22
II (b) 4 Non-Hodgkin lymphomas, NOS	22
II (c) Burkitt lymphoma	23
III CNS and miscellaneous intracranial and intraspinal neoplasms	24
III (a) Ependymomas and choroid plexus tumour	25
III (a) 1 Ependymomas	26

Systematische Darstellung epidemiologischer Kenngrößen der häufigsten ICCC-3 Diagnosen / Systematic Presentation of Descriptive Measures for Frequent ICCC-3 Diagnoses

	Seite / Page
III (a) 2 Choroid plexus tumour	26
III (b) Astrocytomas	27
III (c) Intracranial and intraspinal embryonal tumours	28
III (c) 1 Medulloblastomas	29
III (c) 2 Primitive neuroectodermal tumour (PNET)	29
III (c) 4 Atypical teratoid/rhabdoid tumour	30
III (d) Other gliomas	31
III (d) 1 Oligodendrogliomas	32
III (d) 2 Mixed and unspecified gliomas	32
III (e) Other specified intracranial and intraspinal neoplasms	33
III (e) 1 Pituitary adenomas and carcinomas	34
III (e) 2 Tumours of the sellar region (Craniopharynigiomas)	34
III (e) 3 Pineal parechymal tumours	35
III (e) 4 Neuronal and mixed neuronal-glial tumours	35
III (e) 5 Meningiomas	36
IV (a) Neuroblastoma and ganglioneuroblastom	37
V Retinoblastoma	38
VI (a) Nephroblastoma and other non-epithelial renal tumours	39
VI (a) 1 Nephroblastoma	40

Systematische Darstellung epidemiologischer Kenngrößen der häufigsten ICCC-3 Diagnosen / Systematic Presentation of Descriptive Measures for Frequent ICCC-3 Diagnoses

	Seite / Page
VI (a) 2 Rhabdoid renal tumour	40
VI (b) Renal carcinomas	41
VII (a) Hepatoblastoma	42
VII (b) Hepatic carcinomas	43
VIII Malignant bone tumours	44
VIII (a) Osteosarcomas	45
VIII (c) Ewing tumour and related sarcomas of bone	46
IX Soft tissue and other extraosseous sarcomas	47
IX (a) Rhabdomyosarcomas	48
IX (b) Fibrosarcomas, peripheral nerve sheath tumours and other fibrous neoplasms	49
IX (b) 1 Fibroblastic and myofibroblastic tumours	50
IX (b) 2 Nerve sheath tumours	50
IX (d) Other specified soft tissue sarcomas	51
X Germ cell tumours, trophoblastic tumours and neoplasms of gonads	52
X (a) Intracranial and intraspinal germ cell tumours	53
X (b) Malignant extracranial and extragondal germ cell tumours	54
X (c) Malignant gonadal germ cell tumours	55
XI (a) Adrenocortical carcinomas	56
XI (b) Thyroid carcinomas	57

10 Inhalt / Contents

Systematische Darstellung epidemiologischer Kenngrößen der häufigsten ICCC-3 Diagnosen / Systematic Presentation of Descriptive Measures for Frequent ICCC-3 Diagnoses

	Seite / Page
XI (c) Nasopharyngeal carcinomas	58
XI (d) Malignant melanomas	59
XII (a) Other specified malignant tumours	60

Eingeschlossene Diagnosen entsprechend ICCC-3 (siehe Methoden)

Selected diagnoses according to ICCC-3 (see Methods)

Cases in Germany aged under 15 years (1980-2010): 48397

Selected characteristics (Germany 2001-2010)

Relative frequency:	17876 / 17876 = 100 %		
Relative frequency of trial patients:	93.3 %		
Incidence rates per million:	Girls	Boys	Total
		Doys	Total
Number of cases:	7985	9891	17876
Standardized rate *:	147.3	172.9	160.4
Cumulative incidence:	2130	2504	2322
Sex ratio (m/f):			1.2

Age-specific incidence rates per million:

	<1	1-4	5-9	10-14
Number of cases :	1856	6069	4787	5164
Incidence rate:	265.9	208.1	123.3	121.4
Median age at diagnosis:		5	vears 11	months

	5-year	10-year	15-year
Survival probabilities:	83 %	81 %	80 %

Mortality per million within 10 yrs. of diagnosis (1991-2000):

Ν	umber of deaths	Standardized*	Cumulative
Ν	% of all 4151 deaths	mortality rate	mortality
4151	100.0 %	33.0	479

Second neoplasms (SN) within 20 yrs. of diagnosis (1980-2010): All malignancies

SN after all malignancies			
	% of all	Cumulative	
Ν	775 SN	incidence	
775	100.0 %	3.2 %	

* Standard: Segi world standard population

Survival probabilities by year of diagnosis (Germany 1980-2009)



Age- and sex-specific incidence rates per million (Germany 2001-2010)









I Leukaemias, myeloproliferative and myelodysplastic diseases

(a) Hodgkin lymphomas

12

- (b) Non-Hodgkin lymphomas (except Burkitt lymphoma)
- (c) Burkitt lymphoma

Cases in Germany aged under 15 years (1980-2010): 16684

Selected characteristics (Germany 2001-2010)

Relative frequency:	6089 / 17876 = 34.1 %		
Relative frequency of trial patients:	99.2 %		
Incidence rates per million:	Girls	Boys	Total
Number of cases:	2757	3332	6089
Standardized rate *:	52.2	59.3	55.8
	740	040	707
	742	040	/9/
Sex ratio (m/t):			1.2

Age-specific incidence rates per million:

	<1	1-4	5-9	10-14
Number of cases :	308	2756	1678	1347
Incidence rate:	44.1	94.5	43.2	31.7
Median age at diagnosis:		4	years 11	months

	5-year	10-year	15-yea
Survival probabilities:	87 %	84 %	83 %

Mortality per million within 10 yrs. of diagnosis (1991-2000):

Ν	umber of deaths	Standardized*	Cumulative
Ν	% of all 4151 deaths	mortality rate	mortality
1348	32.5 %	10.6	155

Second neoplasms (SN) within 20 yrs. of diagnosis (1980-2010): I Leukaemias, myeloproliferative and myelodysplastic diseases

SN a	SN after I I as SN after any pr			any primary	
	% of all	Cumulative		% of all	Cumulative
Ν	775 SN	incidence	Ν	775 SN	incidence
285	36.8 %	3.2 %	223	28.8 %	0.7 %

* Standard: Segi world standard population

Survival probabilities by year of diagnosis (Germany 1980-2009)



(d) Myelodysplastic syndrome and other myeloproliferative disease(e) Unspecified and other specified leukaemias









Age- and sex-specific incidence rates per million (Germany 2001-2010)

I (a) Lymphoid leukaemias

Until 2004, the average increase in incidence of Lymphoid Leukaemia (LL) was ca. 0.7% per year. This is similar to Europe. The literature considers this increase as real, not a registration artefact, possibly due to changes in life style. Based on international comparisons, completeness of registration is close to 100%. Compared to all childhood cancers, mortality is relatively low. LL is relatively rare as a second neoplasm.

Cases in Germany aged under 15 years (1980-2010): 13315

Selected characteristics (Germany 2001-2010) 4767 / 17876 = 27.2 % **Relative frequency: Relative frequency of trial patients:** 99.8 % Incidence rates per million: Girls Boys Total Number of cases: 2145 2622 4767 Standardized rate *: 41.0 46.9 44.0 Cumulative incidence: 579 669 625 Sex ratio (m/f): 1.2

Age-specific incidence rates per million:

	<1	1-4	5-9	10-14
Number of cases :	134	2339	1376	918
Incidence rate:	19.2	80.2	35.4	21.6
Median age at diagnosis:	4 years 10 months			

	5-year	10-year	15-yea
Survival probabilities:	90 %	88 %	87 %

Mortality per million within 10 yrs. of diagnosis (1991-2000):

N	umber of deaths	Standardized*	Cumulative
Ν	% of all 4151 deaths	mortality rate	mortality
797	19.2 %	6.3	92

Second neoplasms (SN) within 20 yrs. of diagnosis (1980-2010): I (a) Lymphoid leukaemias

SN after I (a)			l (a)	as SN afte	r any primary
	% of all	Cumulative		% of all	Cumulative
Ν	775 SN	incidence	Ν	775 SN	incidence
238	30.7 %	3.2 %	43	5.5 %	0.1 %

* Standard: Segi world standard population

Survival probabilities by year of diagnosis (Germany 1980-2009)



Age- and sex-specific incidence rates per million (Germany 2001-2010)









14

1

I (a) Lymphoid leukaemias - Extended ICCC-3

Germany (2001-2010)	Ν	%
Lymphoid leukaemias	4767	100.0
Precursor cell leukaemias	4655	97.7
Mature B-cell leukaemias	111	2.3
Mature T-cell and NK cell leukaemias	1	0.0
Lymphoid leukaemia, NOS	0	0.0

Precursor cell leukaemias

Cases in Germany aged under 15 years (1980-2010): 13000

Selected characteristics (Germany 2001-2010)

Relative frequency:	4655 / 17876 = 26.0 %			
Relative frequency of trial patients:			99.8 %	
Incidence rates per million:	Girls	Boys	Total	
Number of cases:	2119	2536	4655	
Standardized rate *:	40.5	45.5	43.0	
Cumulative incidence:	572	647	611	
Sex ratio (m/f):			1.2	
Age-specific incidence rates per million:				

	<1	1-4	5-9	10-14
Number of cases:	131	2313	1326	885
Incidence rate:	18.8	79.3	34.1	20.8
Median age at diagnosis:		4 years 9 months		

* Standard: Segi world standard population

Age- and sex-specific incidence rates per million (Germany 2001-2010



2 Mature B-cell leukaemias

Cases in Germany aged under 15 years (1980-2010): 314

Selected characteristics (Germany 2001-2010)

Relative frequency:	111 / 17876 = 0.6 %		
Relative frequency of trial patients:	s: 99.1 °		99.1 %
Incidence rates per million:	Girls	Boys	Total
Number of cases:	25	86	111
Standardized rate *:	0.4	1.4	0.9
Cumulative incidence:	7	21	14
Sex ratio (m/f):			3.4

Age-specific incidence rates per million: 5-9 10-14 <1 1-4 Number of cases: 3 26 50 32 Incidence rate: 0.4 0.9 1.3 0.8 Median age at diagnosis: 7 years 5 months

Age- and sex-specific incidence rates per million (Germany 2001-2010



* Standard: Segi world standard population

I (b) Acute myeloid leukaemias

Based on international comparisons, completeness of registration of acute myeloid leukaemias (AML) is close to 100%. Compared to all childhood cancers, mortality is relatively high. Prognosis has improved considerably since 1980. AML occurs relatively frequently as a second neoplasm.

Cases in Germany aged under 15 years (1980-2010): 2371

. .

Relative frequency: 795 / 17876 = 4.5 %					
Relative frequency of trial patients:		97.6 %			
Incidence rates per million:	Girls	Boys	Total		
Number of cases:	379	416	795		
Standardized rate *:	7.2	7.4	7.3		
Cumulative incidence:	102	106	104		
Sex ratio (m/f): 1.1					

Age-specific incidence rates per million:

	<1	1-4	5-9	10-14
Number of cases :	115	288	158	234
Incidence rate:	16.5	9.9	4.1	5.5
Median age at diagnosis:	4 years 11 months			

_		
5-year	10-year	15-yea

 Survival probabilities:
 70 %
 68 %
 67 %

Mortality per million within 10 yrs. of diagnosis (1991-2000):

N	umber of deaths	Standardized*	Cumulative
Ν	% of all 4151 deaths	mortality rate	mortality
421	10.1 %	3.3	49

Second neoplasms (SN) within 20 yrs. of diagnosis (1980-2010): I (b) Acute myeloid leukaemias

SN after I (b)			l (b)	as SN afte	r any primary
	% of all	Cumulative		% of all	Cumulative
Ν	775 SN	incidence	Ν	775 SN	incidence
32	4.1 %	2.9 %	124	16.0 %	0.3 %

* Standard: Segi world standard population

Survival probabilities by year of diagnosis (Germany 1980-2009)



Age- and sex-specific incidence rates per million (Germany 2001-2010)









16 I (c) Chronic myeloproliferative diseases

Chronic myeloproliferative (CM) diseases are rare in early childhood. Based on international comparisons, completeness of registration is close to 100%. Second neoplasms after CM diseases are relatively rare, underreporting is a possibility.

Cases in Germany aged under 15 years (1980-2010): 226

Selected characteristics (dermany 200	. 2010,			
Relative frequency: 80 / 17876 = 0.5 %				
Relative frequency of trial patients:			86.3 %	
Incidence rates per million:	Girls	Boys	Total	
Number of cases:	43	37	80	
Standardized rate *:	0.7	0.6	0.6	
Cumulative incidence:	11	9	10	
Sex ratio (m/f): 0.9				

Age-specific incidence rates per million:

	<1	1-4	5-9	10-14
Number of cases :	0	10	29	41
Incidence rate:	0.0	0.3	0.7	1.0
Median age at diagnosis:		1	0 years 3	months

	5-year	10-year	15-yea
Survival probabilities:	-	-	-

Mortality per million within 10 yrs. of diagnosis (1991-2000):

N	lumber of deaths	Standardized*	Cumulative
Ν	% of all 4151 deaths	mortality rate	mortality
33	0.8 %	0.2	4

Second neoplasms (SN) within 20 yrs. of diagnosis (1980-2010): I (c) Chronic myeloproliferative diseases

SN af	fter I (c)		I (c) as SN after any primary		
	% of all	Cumulative		% of all	Cumulative
Ν	775 SN	incidence	Ν	775 SN	incidence
2	0.3 %	1.4 %	3	0.4 %	0.0 %

* Standard: Segi world standard population

Survival probabilities by year of diagnosis (Germany 1980-2009)



Age- and sex-specific incidence rates per million (Germany 2001-2010)



Standardized* annual incidence rates per million (Germany 1980-2010)



Standardized* incidence rates per million by districts (Landkreise) (Germany 2001-2010)

I (d) Myelodysplastic syndrome and other myeloproliferative diseases

Myelodysplastic syndrome (MDS) was reclassified as malignant at the introduction of ICD-O-3, so earlier registration is incomplete. The visible trend is a registration artefact. Prognosis has improved considerably since 1980. MDS is relatively frequently followed by a second neoplasm within 20 years of diagnosis. MDS is relatively frequent as a second neoplasm.

Cases in Germany aged under 15 years (1980-2010): 614

Relative frequency: 377 / 17876 = 2.2 %				
Relative frequency of trial patients:		97.6 %		
Incidence rates per million:	Girls	Boys	Total	
Number of cases:	159	218	377	
Standardized rate *:	2.8	3.8	3.3	
Cumulative incidence:	42	55	48	
Sex ratio (m/f):			1.4	

Age-specific incidence rates per million:

5-9 10-14 <1 1-4 Number of cases : 41 104 97 135 Incidence rate: 5.9 3.6 2.5 3.2 Median age at diagnosis: 7 years 3 months

	5-year	10-year	15-yea
Survival probabilities:	78 %	77 %	75 %

Mortality per million within 10 yrs. of diagnosis (1991-2000):

N	lumber of deaths	Standardized*	Cumulative
Ν	% of all 4151 deaths	mortality rate	mortality
80	1.9 %	0.6	9

Second neoplasms (SN) within 20 yrs. of diagnosis (1980-2010): I (d) Myelodysplastic syndrome and other myeloproliferative dise

SN after I (d) I (d) as SN after any p			r any primary		
	% of all	Cumulative		% of all	Cumulative
Ν	775 SN	incidence	Ν	775 SN	incidence
6	0.8 %	5.8 %	52	6.7 %	0.2 %

* Standard: Segi world standard population

Survival probabilities by year of diagnosis (Germany 1980-2009)



Age- and sex-specific incidence rates per million (Germany 2001-2010)









18 II Lymphomas and reticuloendothelial neoplasms

- (a) Hodgkin lymphomas
- (b) Non-Hodgkin lymphomas (except Burkitt lymphoma)
- (c) Burkitt lymphoma

Cases in Germany aged under 15 years (1980-2010): 5762

Selected characteristics (Germany 2001-2010) 2037 / 17876 = 11.4 % **Relative frequency: Relative frequency of trial patients:** 96.4 % Incidence rates per million: Girls Boys Total Number of cases: 662 1375 2037 Standardized rate *: 10.2 21.1 15.8 Cumulative incidence: 166 333 252 Sex ratio (m/f): 2.1

Age-specific incidence rates per million:

	<1	1-4	5-9	10-14
Number of cases :	13	221	688	1115
Incidence rate:	1.9	7.6	17.7	26.2
Median age at diagnosis:		1	0 years 7	months

	5-year	10-year	15-year
Survival probabilities:	94 %	92 %	91 %

Mortality per million within 10 yrs. of diagnosis (1991-2000):

N	umber of deaths	Standardized*	Cumulative
Ν	% of all 4151 deaths	mortality rate	mortality
225	5.4 %	1.7	26

Second neoplasms (SN) within 20 yrs. of diagnosis (1980-2010): II Lymphomas and reticuloendothelial neoplasms

1	SN aft	er II	II as SN after any prima			any primary
		% of all	Cumulative		% of all	Cumulative
	Ν	775 SN	incidence	Ν	775 SN	incidence
	129	16.6 %	5.1 %	80	10.3 %	0.3 %

* Standard: Segi world standard population

Survival probabilities by year of diagnosis (Germany 1980-2009)



(d) Miscellaneous lymphoreticular neoplasms

Age- and sex-specific incidence rates per million

(e) Unspecified lymphomas









II (a) Hodgkin lymphomas

Hodgkin's diease (HD) is rare in early childhood. Based on international comparisons, completeness of registration is close to 100%. Compared to all childhood cancers, mortality is relatively low. HD is relatively frequently followed by a second neoplasm within 20 years of diagnosis.

ır

Cases in Germany aged under 15 years (1980-2010): 2363

Selected characteristics (Germany 2001-2010) 864 / 17876 = 4.9 % **Relative frequency: Relative frequency of trial patients:** 97.5 % Incidence rates per million: Girls Boys Total Number of cases: 343 521 864 Standardized rate *: 7.6 5.0 6.3 Cumulative incidence: 84 124 104 Sex ratio (m/f): 1.5

Age-specific incidence rates per million:

	<1	1-4	5-9	10-14
Number of cases :	0	33	202	629
Incidence rate:	0.0	1.1	5.2	14.8
Median age at diagnosis:		1	2 years 6	months

Ever	10	15 100

 Survival probabilities:
 98 %
 97 %
 96 %

Mortality per million within 10 yrs. of diagnosis (1991-2000):

N	lumber of deaths	Standardized*	Cumulative
Ν	% of all 4151 deaths	mortality rate	mortality
45	1.1 %	0.3	5

Second neoplasms (SN) within 20 yrs. of diagnosis (1980-2010): II (a) Hodgkin lymphomas

SN after II (a)			II (a)	as SN afte	r any primary
	% of all	Cumulative		% of all	Cumulative
Ν	775 SN	incidence	Ν	775 SN	incidence
66	8.5 %	10.0 %	17	2.2 %	0.1 %

* Standard: Segi world standard population

Survival probabilities by year of diagnosis (Germany 1980-2009)



Age- and sex-specific incidence rates per million (Germany 2001-2010)









Based on international comparisons, completeness of registration is close to 100%. Prognosis has improved considerably since 1980. Burkitt Lymphomas are presented as a separate entity.

Cases in Germany aged under 15 years (1980-2010): 2261

- - -

. .

Selected characteristics (Germany 2001-2010)				
Relative frequency: 800 / 17876 = 4.6 %				
Relative frequency of trial patients: 94.6				
Incidence rotes nor million.	Girlo	Boyo	Total	
incidence rates per minion:	GINS	воуѕ	Total	
Number of cases:	251	549	800	
Standardized rate *:	4.1	8.6	6.4	
Cumulative incidence:	64	134	100	
Sex ratio (m/f):			2.2	

Age-specific incidence rates per million:

	<1	1-4	5-9	10-14
Number of cases :	7	123	309	361
Incidence rate:	1.0	4.2	8.0	8.5
Median age at diagnosis:			9 years 4	months

	5-year	10-year	15-year
Survival probabilities:	88 %	86 %	85 %

Mortality per million within 10 yrs. of diagnosis (1991-2000):

N	umber of deaths	Standardized*	Cumulative
Ν	% of all 4151 deaths	mortality rate	mortality
131	3.2 %	1.0	15

Second neoplasms (SN) within 20 yrs. of diagnosis (1980-2010): II (b) Non-Hodgkin lymphomas

SN after II (b)			ll (b)	as SN afte	r any primary
	% of all	Cumulative		% of all	Cumulative
Ν	775 SN	incidence	Ν	775 SN	incidence
48	6.2 %	3.6 %	52	6.7 %	0.2 %

* Standard: Segi world standard population

Survival probabilities by year of diagnosis (Germany 1980-2009)



Age- and sex-specific incidence rates per million (Germany 2001-2010)









II (b) Non-Hodgkin lymphomas - Extended ICCC-3

Non-Hodgkin lymphomas 800 100	.0
Precursor cell lymphomas 327 40	9
Mature B-cell lymphomas (except Burkitt lymphoma) 156 19	.5
Mature T-cell and NK-cell lymphomas 165 20	.6
Non-Hodgkin lymphomas, NOS 152 19	.0

Precursor cell lymphomas

1

Cases in Germany aged under 15 years (1980-2010): 899

Selected characteristics (Germany 2001-2010)

Relative frequency:	327 / 17876 = 1.8 %				
Relative frequency of trial patie	ents:			95.1 %	
Incidence rates per million:		Girls	Boys	Total	
Number of cases:		105	222	327	
Standardized rate *:		1.8	3.6	2.7	
Cumulative incidence:		27	55	41	
Sex ratio (m/f):				2.1	
Age-specific incidence rates per million:					
	<1	1-4	5-9	10-14	
	-	~ .			

	<1	1-4	5-9	10-14
Number of cases:	5	64	139	119
Incidence rate:	0.7	2.2	3.6	2.8
Median age at diagnosis:		;	8 years 3	months

* Standard: Segi world standard population

Age- and sex-specific incidence rates per million (Germany 2001-2010)



2 Mature B-cell lymphomas (except Burkitt lymphoma)

Cases in Germany aged under 15 years (1980-2010): 350

Selected characteristics (Germany 2001-2010)

Relative frequency:	156	/ 17876 =	= 0.9 %
Relative frequency of trial patients:			96.8 %
Incidence rates per million:	Girls	Boys	Total
Number of cases:	46	110	156
Standardized rate *:	0.7	1.6	1.2
Cumulative incidence:	12	26	19
Sex ratio (m/f):			2.4

Age-specific incidence rates per million: 5-9 10-14 <1 1-4 Number of cases: 0 14 52 90 Incidence rate: 0.0 0.5 1.3 2.1 Median age at diagnosis: 10 years 11 months

* Standard: Segi world standard population

Age- and sex-specific incidence rates per million (Germany 2001-2010)



22

II (b) Non-Hodgkin lymphomas - Extended ICCC-3

Germany (2001-2010)	Ν	%
Non-Hodgkin lymphomas	800	100.0
Precursor cell lymphomas	327	40.9
Mature B-cell lymphomas (except Burkitt lymphoma)	156	19.5
Mature T-cell and NK-cell lymphomas	165	20.6
Non-Hodgkin lymphomas, NOS	152	19.0

3 Mature T-cell and NK-cell lymphomas

Cases in Germany aged under 15 years (1980-2010): 400

Selected characteristics (Germany 2001-2010)

Relative frequency: 165 / 17876 = 0.9 %			
Relative frequency of trial patients:			93.9 %
Incidence rates per million:	Girls	Boys	Total
Number of cases:	59	106	165
Standardized rate *:	0.9	1.7	1.3
Cumulative incidence:	15	26	21
Sex ratio (m/f):			1.8
Age-specific incidence rates per mil	lion:	ſ	I

	<1	1-4	5-9	10-14
Number of cases:	2	25	56	82
Incidence rate:	0.3	0.9	1.4	1.9
Median age at diagnosis:		1	9 years 9	months

* Standard: Segi world standard population

Age- and sex-specific incidence rates per million (Germany 2001-2010)



4 Non-Hodgkin lymphomas, NOS

Cases in Germany aged under 15 years (1980-2010): 612

Selected characteristics (Germany 2001-2010) 152 / 17876 = 0.9 % **Relative frequency:** Relative frequency of trial patients: 92.1 % Incidence rates per million: Girls Boys Total Number of cases: 41 111 152 Standardized rate *: 0.7 1.2 1.7 Cumulative incidence: 11 27 19 Sex ratio (m/f): 2.7

Age-specific incidence rates per million: 10-14 <1 1-4 5-9 0 70 Number of cases: 20 62 Incidence rate: 0.0 0.7 1.6 1.6 Median age at diagnosis: 9 years 8 months

* Standard: Segi world standard population

Age- and sex-specific incidence rates per million (Germany 2001-2010)



II (c) Burkitt lymphoma

23

Burkitt lymphoma (BL) is a subtype of Non-Hodgkin lymphomas. Based on international comparisons, completeness of registration is close to 100% since 1988. Prognosis has improved considerably since 1980. BL is rare as a second neoplasm.

Cases in Germany aged under 15 years (1980-2010): 1018

Relative frequency: 361 / 17876 = 2.1 %					
Relative frequency of trial patients:			98.6 %		
Incidence rates per million:	Girls	Boys	Total		
Number of cases:	63	298	361		
Standardized rate *:	1.0	4.8	3.0		
Cumulative incidence:	16	74	46		
Sex ratio (m/f): 4.7					

Age-specific incidence rates per million:

	<1	1-4	5-9	10-14
Number of cases :	1	63	174	123
Incidence rate:	0.1	2.2	4.5	2.9
Median age at diagnosis:			8 years 3	months

	5-year	10-year	15-yea
Survival probabilities:	95 %	94 %	94 %

Mortality per million within 10 yrs. of diagnosis (1991-2000):

Number of deaths		Standardized*	Cumulative
Ν	% of all 4151 deaths	mortality rate	mortality
33	0.8 %	0.2	4

Second neoplasms (SN) within 20 yrs. of diagnosis (1980-2010): II (c) Burkitt lymphoma

SN after II (c)			II (c) as SN after any primary			
		% of all	Cumulative		% of all	Cumulative
	Ν	775 SN	incidence	Ν	775 SN	incidence
_	15	1.9 %	2.1 %	3	0.4 %	0.0 %

* Standard: Segi world standard population

Survival probabilities by year of diagnosis (Germany 1980-2009)



Age- and sex-specific incidence rates per million











24

III CNS and miscellaneous intracranial and intraspinal neoplasms

- (a) Ependymomas and choroid plexus tumour
- (b) Astrocytomas
- (c) Intracranial and intraspinal embryonal tumours
- (d) Other gliomas
- (e) Other specified intracranial and intraspinal neoplasms
- (f) Unspecified intracranial and intraspinal neoplasms

Cases in Germany aged under 15 years (1980-2010): 10216

Selected characteristics (Germany 2001-2010)

Relative frequency: 4159 / 17876 = 23.3 %			23.3 %
Relative frequency of trial patients:	89.5 %		89.5 %
Incidence rates per million:	Girls	Boys	Total
Number of cases:	1856	2303	4159
Standardized rate *:	33.3	39.3	36.4
Cumulative incidence:	491	579	536
Sex ratio (m/f):			1.2

Age-specific incidence rates per million:

5-9 10-14 1-4 <1 Number of cases : 306 1209 1416 1228 Incidence rate: 43.8 41.5 36.5 28.9 Median age at diagnosis: 6 years 11 months

	5-year	10-year	15-yea
Survival probabilities:	76 %	71 %	69 %

Mortality per million within 10 yrs. of diagnosis (1991-2000):

N	umber of deaths	Standardized*	Cumulative	
Ν	% of all 4151 deaths	mortality rate	mortality	
1184	28.5 %	9.4	137	

Second neoplasms (SN) within 20 yrs. of diagnosis (1980-2010): III CNS and miscellaneous intracranial and intraspinal neoplasms

SN after III			III as SN after any primary			
		% of all	Cumulative		% of all	Cumulative
	Ν	775 SN	incidence	Ν	775 SN	incidence
	137	17.7 %	3.2 %	171	22.1 %	0.7 %

* Standard: Segi world standard population

Survival probabilities by year of diagnosis (Germany 1980-2009)



Age- and sex-specific incidence rates per million (Germany 2001-2010)



Standardized* annual incidence rates per million (Germany 1980-2010)

III (a) Ependymomas and choroid plexus tumour

Non-malignant forms are rare, otherwise completeness of registration exceeds 95% compared to international incidence rates. Ependymomas are relatively rare as second neoplasms.

Cases in Germany aged under 15 years (1980-2010): 1030

Selected characteristics (Germany 2001-2010) Relative frequency: 408 / 17876 = 2.3 %

Relative frequency of trial patients:			91.2 %
Incidence rates per million:	Girls	Boys	Total
Number of cases:	172	236	408
Standardized rate *:	3.4	4.3	3.9
Cumulative incidence:	47	61	54
Sex ratio (m/f):			1.4

Age-specific incidence rates per million:

	<1	1-4	5-9	10-14
Number of cases :	70	179	73	86
Incidence rate:	10.0	6.1	1.9	2.0
Median age at diagnosis:	3 years 9 months			

	5-year	10-year	15-yea
Survival probabilities:	80 %	71 %	68 %

Mortality per million within 10 yrs. of diagnosis (1991-2000):

N	umber of deaths	Standardized*	Cumulative
Ν	% of all 4151 deaths	mortality rate	mortality
138	3.3 %	1.2	16

Second neoplasms (SN) within 20 yrs. of diagnosis (1980-2010): III (a) Ependymomas and choroid plexus tumour

SN after III (a)			III (a) as SN after any primary			
		% of all	Cumulative		% of all	Cumulative
	Ν	775 SN	incidence	Ν	775 SN	incidence
	14	1.8 %	2.8 %	7	0.9 %	0.0 %

* Standard: Segi world standard population

Survival probabilities by year of diagnosis (Germany 1980-2009)

Age- and sex-specific incidence rates per million

(Germany 2001-2010)

III (a) Ependymomas and choroid plexus tumour - Extended ICCC-3

Germany (2001-2010)	Ν	%
Ependymomas and choroid plexus tumour	408	100.0
Ependymomas	322	78.9
Choroid plexus tumour	86	21.1

1 Ependymomas

Cases in Germany aged under 15 years (1980-2010): 833

Selected characteristics (Germany 2001-2010)

Relative frequency: 322 / 17876 = 1.8 %				1.8 %
Relative frequency of trial pa			93.5 %	
Incidence rates per million:		Girls	Boys	Total
Number of cases:		129	193	322
Standardized rate *:		2.5	3.5	3.0
Cumulative incidence:		35	49	42
Sex ratio (m/f): 1.				1.5
Age-specific incidence rates	per mi	llion:		
	<1	1-4	5-9	10-14
Number of cases:	28	151	66	77
Incidence rate:	4.0	5.2	1.7	1.8
Median age at diagnosis: 4 years 2 months				

* Standard: Segi world standard population

Age- and sex-specific incidence rates per million (Germany 2001-2010)

2 Choroid plexus tumour

Cases in Germany aged under 15 years (1980-2010): 197

Selected characteristics (Germany 2001-2010)

•	-				
Relative frequency: 86 / 17876 = 0.5 %					
Relative frequency of trial p			82.6 %		
Incidence rates per million:		Girls	Boys	Total	
Number of cases:		43	43	86	
Standardized rate *:		0.9	0.9	0.9	
Cumulative incidence:		12	11	12	
Sex ratio (m/f):				1.0	
Age-specific incidence rates	s per mi	llion:			
	<1	1-4	5-9	10-14	
Number of cases:	42	28	7	9	

6.0

1.0

0.2

1 year 2 months

0.2

* Standard: Segi world standard population

Incidence rate:

Median age at diagnosis:

Age- and sex-specific incidence rates per million (Germany 2001-2010)

26

27

Non-malignant forms of astrocytoma are frequent and may be underreported. The temporal trend is due to improvements in registration. Astrocytomas are relatively rarely followed by a second neoplasm within 20 years of diagnosis.

Cases in Germany aged under 15 years (1980-2010): 4441

- - -

. .

Relative frequency: 1962 / 17876 = 11.2 %					
Relative frequency of trial patients:					
Incidence rates per million:	Girls	Boys	Total		
Number of cases:	922	1040	1962		
Standardized rate *:	16.3	17.5	16.9		
Cumulative incidence:	243	260	252		
Sex ratio (m/f): 1.1					

Age-specific incidence rates per million:

	<1	1-4	5-9	10-14
Number of cases :	97	550	692	623
Incidence rate:	13.9	18.9	17.8	14.7
Median age at diagnosis:		7 years 3 months		

	5-year	10-year	15-yea
Survival probabilities:	80 %	77 %	75 %

Mortality per million within 10 yrs. of diagnosis (1991-2000):

Number of deaths		Standardized*	Cumulative
Ν	% of all 4151 deaths	mortality rate	mortality
384	9.3 %	2.9	44

Second neoplasms (SN) within 20 yrs. of diagnosis (1980-2010): III (b) Astrocytomas

SN after III (b)			III (b)	as SN afte	r any primary
	% of all	Cumulative		% of all	Cumulative
Ν	775 SN	incidence	Ν	775 SN	incidence
32	4.1 %	1.9 %	80	10.3 %	0.3 %

* Standard: Segi world standard population

Survival probabilities by year of diagnosis (Germany 1980-2009)

Age- and sex-specific incidence rates per million (Germany 2001-2010)

28 III (c) Intracranial and intraspinal embryonal tumours

All registered tumours are malignant. Based on international comparisons, completeness of registration exceeds 95%. Compared to all childhood cancers, mortality is relatively high. These tumours are relatively frequently followed by a second neoplasm within 20 years of diagnosis. These tumours are relatively rare as second neoplasms.

Cases in Germany aged under 15 years (1980-2010): 2374

Belative frequency: $831 / 17876 = 4.7 \%$						
4.04						
.4 %						
otal						
831						
7.6						
109						
Sex ratio (m/f): 1.6						

Age-specific incidence rates per million:

	<1	1-4	5-9	10-14
Number of cases :	88	275	322	146
Incidence rate:	12.6	9.4	8.3	3.4
Median age at diagnosis:		5 years 10 months		

	5-year	10-year	15-yea
Survival probabilities:	66 %	59 %	56 %

Mortality per million within 10 yrs. of diagnosis (1991-2000):

Number of deaths		Standardized*	Cumulative
Ν	% of all 4151 deaths	mortality rate	mortality
459	11.1 %	3.8	53

Second neoplasms (SN) within 20 yrs. of diagnosis (1980-2010): III (c) Intracranial and intraspinal embryonal tumours

SN after III (c)			III (c)	as SN afte	r any primary	
		% of all	Cumulative		% of all	Cumulative
	Ν	775 SN	incidence	Ν	775 SN	incidence
-	72	9.3 %	6.3 %	14	1.8 %	0.1 %

* Standard: Segi world standard population

Survival probabilities by year of diagnosis (Germany 1980-2009)

Age- and sex-specific incidence rates per million (Germany 2001-2010)

Standardized* annual incidence rates per million (Germany 1980-2010)

III (c) Intracranial and intraspinal embryonal tumours - Extended ICCC-3

6 years 8 months

Germany (2001-2010)	Ν	%
Intracranial and intraspinal embryonal tumours	831	100.0
Medulloblastomas	595	71.6
Primitive neuroectodermal tumour (PNET)	107	12.9
Medulloepithelioma	7	0.8
Atypical teratoid/rhabdoid tumour	122	14.7

1 Medulloblastomas

Cases in Germany aged under 15 years (1980-2010): 1820

based on International Classification of Childhood Cancer, 3rd edition

Selected characteristics (Germany 2001-2010)

Relative frequency: 595 / 17876 = 3.3			= 3.3 %	
Relative frequency of trial patients:				98.5 %
Incidence rates per million:		Girls	Boys	Total
Number of cases:		223	372	595
Standardized rate *:		4.0	6.4	5.2
Cumulative incidence:		59	94	77
Sex ratio (m/f): 1.7				
Age-specific incidence rates	per mi	llion:		
	<1	1-4	5-9	10-14
Number of cases:	23	172	278	122
Incidence rate:	3.3	5.9	7.2	2.9

* Standard: Segi world standard population

Median age at diagnosis:

Age- and sex-specific incidence rates per million (Germany 2001-2010)

2 Primitive neuroectodermal tumour (PNET)

Cases in Germany aged under 15 years (1980-2010): 376

Selected characteristics (Germany 2001-2010)

Relative frequency:	107 / 17876 = 0.6 %		
Relative frequency of trial patients:			93.5 %
Incidence rates per million:	Girls	Boys	Total
Number of cases:	44	63	107
Standardized rate *:	0.9	1.1	1.0
Cumulative incidence:	12	16	14
Sex ratio (m/f):			1.4

Age-specific incidence rates per million: 10-14 <1 1-4 5-9 Number of cases: 9 51 26 21 Incidence rate: 1.3 1.7 0.7 0.5 Median age at diagnosis: 4 years 3 months

* Standard: Segi world standard population

Age- and sex-specific incidence rates per million (Germany 2001-2010)

29

III (c) Intracranial and intraspinal embryonal tumours - Extended ICCC-3

30

Germany (2001-2010)	Ν	%
Intracranial and intraspinal embryonal tumours	831	100.0
Medulloblastomas	595	71.6
Primitive neuroectodermal tumour (PNET)	107	12.9
Medulloepithelioma	7	0.8
Atypical teratoid/rhabdoid tumour	122	14.7

4

Atypical teratoid/rhabdoid tumour

Cases in Germany aged under 15 years (1980-2010): 162

Selected characteristics (Germany 2001-2010)

Relative frequency:	122 / 17876 = 0.7 %		
Relative frequency of trial patients:			61.5 %
Incidence rates per million:	Girls	Boys	Total
Number of cases:	47	75	122
Standardized rate *:	1.0	1.5	1.3
Cumulative incidence:	13	20	17
Sex ratio (m/f):			1.6

Age-specific incidence rates per million:					
	<1	1-4	5-9	10-14	
Number of cases:	53	50	16	3	
Incidence rate:	7.6	1.7	0.4	0.1	
Median age at diagnosis: 1 year 4 months					

* Standard: Segi world standard population

Age- and sex-specific incidence rates per million (Germany 2001-2010)

III (d) Other gliomas

31

All registered tumours are malignant. Based on international comparisons, completeness of registration approaches 95%. The temporal trend is due to improvements in registration. Gliomas are relatively rarely followed by a second neoplasm (SN) within 20 years of diagnosis, underreporting of SN is a possibility.

Cases in Germany aged under 15 years (1980-2010): 743

. .

Relative frequency: 342 / 17876 = 2.0 %				
Relative frequency of trial patients:			83.3 %	
Incidence rates per million:	Girls	Bovs	Total	
Number of cases:	167	175	342	
Standardized rate *:	2.9	2.9	2.9	
Cumulative incidence:	44	44	44	
Sex ratio (m/f):			1.0	

Age-specific incidence rates per million:

	<1	1-4	5-9	10-14
Number of cases :	16	82	130	114
Incidence rate:	2.3	2.8	3.3	2.7
Median age at diagnosis:			7 years 8	months

	5-year	10-year	15-yea
Survival probabilities:	42 %	41 %	41 %

Mortality per million within 10 yrs. of diagnosis (1991-2000):

N	umber of deaths	Standardized*	Cumulative
Ν	% of all 4151 deaths	mortality rate	mortality
123	3.0 %	0.9	14

Second neoplasms (SN) within 20 yrs. of diagnosis (1980-2010): III (d) Other gliomas

SN af	ter III (d)		III (d) as SN after any primary			
	% of all	Cumulative		% of all	Cumulative	
Ν	775 SN	incidence	Ν	775 SN	incidence	
6	0.8 %	1.3 %	19	2.5 %	0.1 %	

* Standard: Segi world standard population

Survival probabilities by year of diagnosis (Germany 1980-2009)

Age- and sex-specific incidence rates per million

Standardized* annual incidence rates per million (Germany 1980-2010)

32

III (d) Other gliomas - Extended ICCC-3

Germany (2001-2010)	Ν	%
Other gliomas	342	100.0
Oligodendrogliomas	20	5.8
Mixed and unspecified gliomas	308	90.1
Neuroepithelial glial tumours of uncertain origin	14	4.1

Oligodendrogliomas

Cases in Germany aged under 15 years (1980-2010): 110

Selected characteristics (Germany 2001-2010)

Relative frequency:		20 / 17876 = 0.1 %			
Relative frequency of trial pati	ents:			70.0 %	
Incidence rates per million:		Girls	Boys	Total	
Number of cases:		10	10	20	
Standardized rate *:		0.2	0.1	0.2	
Cumulative incidence:		3	2	2	
Sex ratio (m/f):				1.0	
Age-specific incidence rates per million:					
	<1	1-4	5-9	10-14	
Number of cases:	0	1	9	10	

Incidence rate:0.00.00.20.2Median age at diagnosis:10 years 5 months

* Standard: Segi world standard population

Age- and sex-specific incidence rates per million (Germany 2001-2010)

2 Mixed and unspecified gliomas

Cases in Germany aged under 15 years (1980-2010): 611

Selected characteristics (Germany 2001-2010)

Relative frequency:	308 / 17876 = 1.7 %		
Relative frequency of trial patients:			84.1 %
Incidence rates per million:	Girls	Boys	Total
Number of cases:	150	158	308
Standardized rate *:	2.6	2.6	2.6
Cumulative incidence:	39	39	39
Sex ratio (m/f):			1.1

Age-specific incidence rates per million:				
	<1	1-4	5-9	10-14
Number of cases:	14	79	121	94
Incidence rate:	2.0	2.7	3.1	2.2
Median age at diagnosis: 7 years 7 months				

* Standard: Segi world standard population

Age- and sex-specific incidence rates per million (Germany 2001-2010)

III (e) Other specified intracranial and intraspinal neoplasms

Non-malignant forms are frequent and may be underreported. The temporal trend is due to improvements in registration. These tumours are relatively rarely followed by a second neoplasm (SN) within 20 years of diagnosis, underreporting of SN is a possibility. These tumours are relatively frequent as second neoplasms.

Cases in Germany aged under 15 years (1980-2010): 1265

. .

8.1 %				
3.5 %				
Tatal				
lotal				
550				
4.5				
69				
Sex ratio (m/f): 1.2				

Age-specific incidence rates per million:

	<1	1-4	5-9	10-14
Number of cases :	22	109	182	237
Incidence rate:	3.2	3.7	4.7	5.6
Median age at diagnosis:			9 vears 2	months

	5-year	10-year	15-yea
Survival probabilities:	95 %	93 %	90 %

Mortality per million within 10 yrs. of diagnosis (1991-2000):

N	umber of deaths	Standardized*	Cumulative
Ν	% of all 4151 deaths	mortality rate	mortality
32	0.8 %	0.2	4

Second neoplasms (SN) within 20 yrs. of diagnosis (1980-2010): III (e) Other specified intracranial and intraspinal neoplasms

SN af	ter III (e)		III (e) as SN after any primar		
	% of all	Cumulative		% of all	Cumulative
Ν	775 SN	incidence	Ν	775 SN	incidence
12	1.5 %	2.4 %	46	5.9 %	0.3 %

* Standard: Segi world standard population

Survival probabilities by year of diagnosis (Germany 1980-2009)

Age- and sex-specific incidence rates per million (Germany 2001-2010)

33

Standardized* annual incidence rates per million (Germany 1980-2010)

34

III (e) Other specified intracranial and intraspinal neoplasms - Extended ICCC-3

Germany (2001-2010)	Ν	%
Other specified intracranial and intraspinal neoplasms	550	100.0
Pituitary adenomas and carcinomas	30	5.5
Tumours of the sellar region (craniopharyngiomas)	194	35.3
Pineal parenchymal tumours	30	5.5
Neuronal and mixed neuronal-glial tumours	243	44.2
Meningiomas	53	9.6

Pituitary adenomas and carcinomas

Cases in Germany aged under 15 years (1980-2010): 77

Selected characteristics (Germany 2001-2010)

30 / 17876 = 0.2 % **Relative frequency: Relative frequency of trial patients:** 63.3 % Incidence rates per million: Girls Boys Total Number of cases: 15 15 30 Standardized rate *: 0.2 0.2 0.2 Cumulative incidence: 4 3 4 Sex ratio (m/f): 1.0 Age-specific incidence rates per million: <1 1-4 5-9 10-14 Number of cases: 0 3 3 24 Incidence rate: 0.0 0.1 0.1 0.6 Median age at diagnosis: 12 years 9 months

* Standard: Segi world standard population

Age- and sex-specific incidence rates per million (Germany 2001-2010)

2 Tumours of the sellar region (craniopharyngiomas)

Cases in Germany aged under 15 years (1980-2010): 520

Selected characteristics (Germany 2001-2010)

Relative frequency:	194 / 17876 = 1.1 %			
Relative frequency of trial patients:			97.4 %	
Incidence rates per million:	Girls	Boys	Total	
Number of cases:	94	100	194	
Standardized rate *:	1.6	1.6	1.6	
Cumulative incidence:	24	25	24	
Sex ratio (m/f): 1.1				
Age-specific incidence rates per million:				

	<1	1-4	5-9	10-14
Number of cases:	1	38	80	75
ncidence rate:	0.1	1.3	2.1	1.8
Median age at diagnosis:		8	years 10	months

* Standard: Segi world standard population

Age- and sex-specific incidence rates per million (Germany 2001-2010)

Germany (2001-2010)	Ν	%
Other specified intracranial and intraspinal neoplasms	550	100.0
Pituitary adenomas and carcinomas	30	5.5
Tumours of the sellar region (craniopharyngiomas)	194	35.3
Pineal parenchymal tumours	30	5.5
Neuronal and mixed neuronal-glial tumours	243	44.2
Meningiomas	53	9.6

3 Pineal parenchymal tumours

Cases in Germany aged under 15 years (1980-2010): 109

Selected characteristics (Germany 2001-2010) 30 / 17876 = 0.2 % **Relative frequency: Relative frequency of trial patients:** 86.7 % Incidence rates per million: Girls Boys Total Number of cases: 13 17 30 Standardized rate *: 0.2 0.3 0.3 Cumulative incidence: 3 4 4 Sex ratio (m/f): 1.3 Age-specific incidence rates per million: <1 1-4 5-9 10-14 Number of cases: 1 9 9 11 Incidence rate: 0.1 0.3 0.2 0.3 Median age at diagnosis: 7 years 10 months

* Standard: Segi world standard population

Age- and sex-specific incidence rates per million (Germany 2001-2010)

4 Neuronal and mixed neuronal-glial tumours

Cases in Germany aged under 15 years (1980-2010): 433

Selected characteristics (Germany 2001-2010)

Relative frequency:	243 / 17876 = 1.4 %		
Relative frequency of trial patients:	: 87.7 °		87.7 %
Incidence rates per million:	Girls	Boys	Total
Number of cases:	100	143	243
Standardized rate *:	1.7	2.3	2.0
Cumulative incidence:	26	35	31
Sex ratio (m/f):			1.4

Age-specific incidence rates per million: <1 1-4 5-9 10-14 Number of cases: 20 48 70 105 Incidence rate: 2.9 1.6 1.8 2.5 Median age at diagnosis: 8 years 8 months

* Standard: Segi world standard population

Age- and sex-specific incidence rates per million (Germany 2001-2010)

35

III (e) Other specified intracranial and intraspinal neoplasms - Extended ICCC-3

Germany (2001-2010)	Ν	%
Other specified intracranial and intraspinal neoplasms	550	100.0
Pituitary adenomas and carcinomas	30	5.5
Tumours of the sellar region (craniopharyngiomas)	194	35.3
Pineal parenchymal tumours	30	5.5
Neuronal and mixed neuronal-glial tumours	243	44.2
Meningiomas	53	9.6

5 Meningiomas

Cases in Germany aged under 15 years (1980-2010): 126

Selected characteristics (Germany 2001-2010)

Relative frequency: 53 / 17876 = 0.3			• 0.3 %	
Relative frequency of trial pa	tients:			75.5 %
Incidence rates per million:		Girls	Boys	Total
Number of cases:		28	25	53
Standardized rate *:	rdized rate *: 0.5 0.4			0.4
Cumulative incidence:	7	6	7	
Sex ratio (m/f): 0.9				
Age-specific incidence rates	per mi	llion:		
	<1	1-4	5-9	10-14
Number of cases:	0	11	20	22
Incidence rate:	0.0	0.4	0.5	0.5
Median age at diagnosis:8 years 10 months				

* Standard: Segi world standard population

Age- and sex-specific incidence rates per million (Germany 2001-2010)

IV (a) Neuroblastoma and ganglioneuroblastoma

Neuroblastoma (NB) is an embryonal tumor of early childhood. Spontaneous regression has been observed. A large study showed that screening does not reduce mortality. The higher incidence rate 1995-2001 is due to the screening study. Based on international comparisons, completeness of registration is close to 100%. Prognosis has improved considerably since 1980. NB is very rare as a second neoplasm.

Cases in Germany aged under 15 years (1980-2010): 3690

Selected characteristics (Germany 2001-2010) 1240 / 17876 = 7.1 % **Relative frequency: Relative frequency of trial patients:** 99.0 % Incidence rates per million: Girls Boys Total Number of cases: 570 670 1240 Standardized rate *: 12.5 14.1 13.3 Cumulative incidence: 162 182 172 Sex ratio (m/f): 1.2

Age-specific incidence rates per million: 10-14 1-4 5-9 <1 Number of cases : 575 536 101 28 Incidence rate: 82.4 18.4 2.6 0.7 Median age at diagnosis: 1 year 2 months

	5-year	10-year	15-year
Survival probabilities:	78 %	75 %	74 %

Mortality per million within 10 yrs. of diagnosis (1991-2000):

N	umber of deaths	Standardized*	Cumulative
Ν	% of all 4151 deaths	mortality rate	mortality
445	10.7 %	3.9	53

Second neoplasms (SN) within 20 yrs. of diagnosis (1980-2010): IV (a) Neuroblastoma and ganglioneuroblastoma

ę	SN af	ter IV (a)		IV (a)	as SN afte	r any primary
		% of all	Cumulative		% of all	Cumulative
	Ν	775 SN	incidence	Ν	775 SN	incidence
_	49	6.3 %	2.5 %	9	1.2 %	0.0 %

* Standard: Segi world standard population

Survival probabilities by year of diagnosis (Germany 1980-2009)

Age- and sex-specific incidence rates per million (Germany 2001-2010)

38 V Retinoblastoma

Retinoblastoma (RB) is an embryonal tumor of early childhood. The gene variant leading to RB is known. Hereditary cases are earlier than spontaneous mutations and often bilateral. Based on international comparisons, completeness of registration is close to 100%. RB is very rare as a second neoplasm.

Cases in Germany aged under 15 years (1980-2010): 1170

Relative frequency: 396 / 17876 = 2.3 %						
-						
al						
6						
.3						
55						
Sex ratio (m/f): 1.2						

Age-specific incidence rates per million:

	<1	1-4	5-9	10-14
Number of cases :	173	203	18	2
Incidence rate:	24.8	7.0	0.5	0.0
Median age at diagnosis:			1 year 2	months

	5-year	10-year	15-year
Survival probabilities:	98 %	98 %	98 %

Mortality per million within 10 yrs. of diagnosis (1991-2000):

١	lumber of deaths	Standardized*	Cumulative
Ν	% of all 4151 deaths	mortality rate	mortality
9	0.2 %	0.1	1

Second neoplasms (SN) within 20 yrs. of diagnosis (1980-2010): V Retinoblastoma

SN af	ter V		V as SN after any primary		
	% of all	Cumulative		% of all	Cumulative
Ν	775 SN	incidence	Ν	775 SN	incidence
24	3.1 %	3.1 %	3	0.4 %	0.0 %

* Standard: Segi world standard population

Survival probabilities by year of diagnosis (Germany 1980-2009)

Age- and sex-specific incidence rates per million (Germany 2001-2010)

Standardized* annual incidence rates per million (Germany 1980-2010)

VI (a) Nephroblastoma and other non-epithelial renal tumours

Nephroblastoma is an embryonal tumor of early childhood. Based on international comparisons, completeness of registration is close to 100%. Nephroblastoma is rare as a second neoplasm.

Cases in Germany aged under 15 years (1980-2010): 2823

Selected characteristics (Germany 2001-2010)

Relative frequency:	980 / 17876 = 5.6 %			
Relative frequency of trial patients:	98.7 %			
Incidence rates per million:	Girls	Bovs	Total	
Number of cases:	509	471	980	
Standardized rate *:	10.5	9.3	9.9	
Cumulative incidence:	141	125	133	
Sex ratio (m/f):			0.9	

Age-specific incidence rates per million:

	<1	1-4	5-9	10-14
Number of cases :	167	557	212	44
Incidence rate:	23.9	19.1	5.5	1.0
Median age at diagnosis:			3 years	1 month

	5-year	10-year	15-yea
Survival probabilities:	93 %	93 %	92 %

Mortality per million within 10 yrs. of diagnosis (1991-2000):

Number of deaths		Standardized*	Cumulative
Ν	% of all 4151 deaths	mortality rate	mortality
123	3.0 %	1.1	15

Second neoplasms (SN) within 20 yrs. of diagnosis (1980-2010): VI (a) Nephroblastoma and other non-epithelial renal tumours

	SN af	fter VI (a)		VI (a) as SN after any primary		
		% of all	Cumulative		% of all	Cumulative
	Ν	775 SN	incidence	Ν	775 SN	incidence
-	31	4.0 %	2.1 %	8	1.0 %	0.0 %

* Standard: Segi world standard population

Survival probabilities by year of diagnosis (Germany 1980-2009)

Age- and sex-specific incidence rates per million

(Germany 2001-2010)

39

40

1

VI (a) Nephroblastoma and other non-epithelial renal tumours - Extended ICCC-3

Germany (2001-2010)	Ν	%	
Nephroblastoma and other non-epithelial renal tumours	980	100.0	
Nephroblastoma	959	97.9	
Rhabdoid renal tumour	13	1.3	
Kidney sarcomas	7	0.7	
Peripheral neuroectodermal tumour (pPNET) of kidney	1	0.1	

Nephroblastoma

Cases in Germany aged under 15 years (1980-2010): 2732

Selected characteristics (Germany 2001-2010)

Relative frequency:		959 / 17876 = 5.4 %		
Relative frequency of trial	patients:			99.0 %
Incidence rates per million	:	Girls	Boys	Total
Number of cases:		501	458	959
Standardized rate *:		10.3	9.1	9.7
Cumulative incidence:		139	121	130
Sex ratio (m/f):				0.9
Age-specific incidence rates per million:				
	<1	1-4	5-9	10-14
Number of cases:	159	550	208	42

Median age at diagnosis:	22.0	10.5	3 years 1	month
Incidence rate:	22.8	18.9	54	10
Number of cases:	159	550	208	42

* Standard: Segi world standard population

Age- and sex-specific incidence rates per million (Germany 2001-2010)

2 Rhabdoid renal tumour

Cases in Germany aged under 15 years (1980-2010): 45

Selected characteristics (Germany 2001-2010)

Relative frequency:	13 / 17876 = 0.1 %		
Relative frequency of trial patients:			76.9 %
Incidence rates per million:	Girls	Boys	Total
Number of cases:	6	7	13
Standardized rate *:	0.1	0.1	0.1
Cumulative incidence:	2	2	2
Sex ratio (m/f):			1.2

Age-specific incidence rates per million: 5-9 10-14 <1 1-4 Number of cases: 8 4 1 0 Incidence rate: 1.1 0.1 0.0 0.0 Median age at diagnosis: 0 years 10 months

* Standard: Segi world standard population

Age- and sex-specific incidence rates per million (Germany 2001-2010)

Renal carcinomas are very rare in childhood and rarely treated in pediatric oncology units. Registration is likely to be incomplete.

Cases in Germany aged under 15 years (1980-2010): 53

Selected characteristics (Germany 2001-2010)

Relative frequency:	24 / 17876 = 0.1 %		
Relative frequency of trial patients:			70.8 %
Incidence rates per million:	Girls	Boys	Total
	Ging	20,3	Total
Number of cases:	14	10	24
Standardized rate *:	0.2	0.1	0.2
Cumulative incidence:	4	2	3
Sex ratio (m/f):			0.7

Age-specific incidence rates per million:

	<1	1-4	5-9	10-14
Number of cases :	0	1	6	17
Incidence rate:	0.0	0.0	0.2	0.4
Median age at diagnosis:		1	1 years 9	months

	5-year	10-year	15-year
Survival probabilities:	-	-	-

Mortality per million within 10 yrs. of diagnosis (1991-2000):

1	Number of deaths	Standardized*	Cumulative
Ν	% of all 4151 deaths	mortality rate	mortality
3	0.1 %	0.0	0

Second neoplasms (SN) within 20 yrs. of diagnosis (1980-2010): VI (b) Renal carcinomas

SN af	ter VI (b)		VI (b) as SN after any primary		
	% of all	Cumulative		% of all	Cumulative
Ν	775 SN	incidence	Ν	775 SN	incidence
1	0.1 %	2.3 %	4	0.5 %	0.0 %

* Standard: Segi world standard population

Survival probabilities by year of diagnosis (Germany 1980-2009)

Age- and sex-specific incidence rates per million

(Germany 2001-2010)

Standardized* incidence rates per million by districts (Landkreise) (Germany 2001-2010)

Hepatoblastoma is an embryonal tumor of early childhood. Based on international comparisons, completeness of registration is close to 100%. Prognosis has improved considerably since 1980.

Cases in Germany aged under 15 years (1980-2010): 404

Relative frequency:	179) / 17876 -	= 1.0 %
Relative frequency of trial patients:			98.9 %
Incidence rates per million:	Girls	Boys	Total
Number of cases:	73	106	179
Standardized rate *:	1.6	2.2	1.9
Cumulative incidence:	21	28	25
Sex ratio (m/f):			1.5

Age-specific incidence rates per million:

	<1	1-4	5-9	10-14
Number of cases :	60	99	11	9
Incidence rate:	8.6	3.4	0.3	0.2
Median age at diagnosis:			1 year 5	months

	5-year	10-year	15-year
Survival probabilities:	75 %	74 %	74 %

Mortality per million within 10 yrs. of diagnosis (1991-2000):

N	lumber of deaths	Standardized*	Cumulative
Ν	% of all 4151 deaths	mortality rate	mortality
37	0.9 %	0.3	4

Second neoplasms (SN) within 20 yrs. of diagnosis (1980-2010): VII (a) Hepatoblastoma

SN af	ter VII (a)		VII (a)	as SN aft	er any primary
	% of all	Cumulative		% of all	Cumulative
Ν	775 SN	incidence	Ν	775 SN	incidence
3	0.4 %	2.8 %	2	0.3 %	0.0 %

* Standard: Segi world standard population

Survival probabilities by year of diagnosis (Germany 1980-2009)

Age- and sex-specific incidence rates per million (Germany 2001-2010)

Standardized* annual incidence rates per million (Germany 1980-2010)

Standardized* incidence rates per million by districts (Landkreise) (Germany 2001-2010)

VII (b) Hepatic carcinomas

Hepatic carcinomas are rare in childhood. Registration may be incomplete. Prognosis has improved considerably since 1980. So far, no second neoplasm (SN) has been observed after a hepatic carcinoma within 20 years of diagnosis, underreporting of SN is a possibility.

Cases in Germany aged under 15 years (1980-2010): 100

. .

Selected characteristics (Germany 20	01-2010)		
Relative frequency:	36	6 / 17876 -	= 0.2 %
Relative frequency of trial patients:			80.6 %
		_	
Incidence rates per million:	Girls	Boys	Total
Number of cases:	13	23	36
Standardized rate *:	0.2	0.3	0.3
Cumulative incidence:	3	5	4
Sex ratio (m/f):			1.8

Age-specific incidence rates per million:

. .

	<1	1-4	5-9	10-14
Number of cases :	0	3	11	22
Incidence rate:	0.0	0.1	0.3	0.5
Median age at diagnosis:	12 years 6 months			

	5-year	10-year	15-year
Survival probabilities:	-	-	-

Mortality per million within 10 yrs. of diagnosis (1991-2000):

N	lumber of deaths	Standardized*	Cumulative
Ν	% of all 4151 deaths	mortality rate	mortality
16	0.4 %	0.1	2

Second neoplasms (SN) within 20 yrs. of diagnosis (1980-2010): VII (b) Hepatic carcinomas

SN af	ter VII (b)		VII (b) as SN afte	er any primary
	% of all	Cumulative		% of all	Cumulative
Ν	775 SN	incidence	Ν	775 SN	incidence
0	0.0 %	0.0 %	4	0.5 %	0.0 %

* Standard: Segi world standard population

Survival probabilities by year of diagnosis (Germany 1980-2009)

Age- and sex-specific incidence rates per million

Standardized* incidence rates per million by districts (Landkreise) (Germany 2001-2010)

44 VIII Malignant bone tumours

- (a) Osteosarcomas
- (b) Chondrosarcomas
- (c) Ewing tumour and related sarcomas of bone

Cases in Germany aged under 15 years (1980-2010): 2285

Selected characteristics (Germany 2001-2010)				
Relative frequency:	802	2 / 17876 :	= 4.5 %	
Relative frequency of trial patients: 97.6			97.6 %	
lu siden es vetes nev million.	Cirla	Davia	Tatal	
incidence rates per million:	GINS	Boys	Total	
Number of cases:	379	423	802	
Standardized rate *:	5.8	6.2	6.0	
Cumulative incidence:	95	101	98	
Sex ratio (m/f): 1.1				

Age-specific incidence rates per million:

	<1	1-4	5-9	10-14
Number of cases :	5	51	209	537
Incidence rate:	0.7	1.7	5.4	12.6
Median age at diagnosis:		1	1 years 8	months

|--|

 Survival probabilities:
 73 %
 69 %
 68 %

Mortality per million within 10 yrs. of diagnosis (1991-2000):

Number of deaths		Standardized*	Cumulative
Ν	% of all 4151 deaths	mortality rate	mortality
265	6.4 %	1.8	30

Second neoplasms (SN) within 20 yrs. of diagnosis (1980-2010): VIII Malignant bone tumours

SN after VIII			VIII a	as SN after	any primary
	% of all	Cumulative		% of all	Cumulative
Ν	775 SN	incidence	Ν	775 SN	incidence
42	5.4 %	3.0 %	48	6.2 %	0.2 %

* Standard: Segi world standard population

Survival probabilities by year of diagnosis (Germany 1980-2009)

- (d) Other specified malignant bone tumours
- (e) Unspecified malignant bone tumours
- Age- and sex-specific incidence rates per million (Germany 2001-2010)

Osteosarcomas are rare in early childhood. Based on international comparisons, completeness of registration exceeds 95%. Osteosarcomas are relatively frequent as second neoplasms.

Cases in Germany aged under 15 years (1980-2010): 1200

- - -

. .

	51 2010)			
Relative frequency: 410 / 17876 = 2.3 %				
Relative frequency of trial patients:			98.3 %	
Incidence rates per million:	Girls	Boys	Total	
Number of cases:	204	206	410	
Standardized rate *:	3.0	2.9	3.0	
Cumulative incidence:	50	48	49	
Sex ratio (m/f):			1.0	

Age-specific incidence rates per million:

	<1	1-4	5-9	10-14
Number of cases :	0	11	89	310
Incidence rate:	0.0	0.4	2.3	7.3
Median age at diagnosis:		1	2 years 4	months

5-year | 10-year | 15-year

Survival probabilities:	75 %	71 %	70 °

Mortality per million within 10 yrs. of diagnosis (1991-2000):

Number of deaths		Standardized*	Cumulative
Ν	% of all 4151 deaths	mortality rate	mortality
137	3.3 %	0.9	15

Second neoplasms (SN) within 20 yrs. of diagnosis (1980-2010): VIII (a) Osteosarcomas

SN after VIII (a)			VIII (a) as SN aft	er any primary
	% of all	Cumulative		% of all	Cumulative
N	775 SN	incidence	Ν	775 SN	incidence
16	6 2.1 %	2.2 %	33	4.3 %	0.1 %

* Standard: Segi world standard population

Survival probabilities by year of diagnosis (Germany 1980-2009)

Age- and sex-specific incidence rates per million (Germany 2001-2010)

VIII (c) Ewing tumour and related sarcomas of bone

Based on international comparisons, completeness of registration exceeds 95%.

Cases in Germany aged under 15 years (1980-2010): 1010

Relative frequency: 361 / 17876 = 2.1 %					
Relative frequency of trial patients:			99.2 %		
Incidence rates per million:	Girls	Boys	Total		
Number of cases:	157	204	361		
Standardized rate *:	2.5	3.1	2.8		
Cumulative incidence:	40	49	45		
Sex ratio (m/f): 1.3					

Age-specific incidence rates per million:

	<1	1-4	5-9	10-14
Number of cases :	5	37	112	207
Incidence rate:	0.7	1.3	2.9	4.9
Median age at diagnosis:		1	0 years 9	months

5-year 10-year 15-year

Survival probabilities:	71 %	66 %	65 %

Mortality per million within 10 yrs. of diagnosis (1991-2000):

Number of deaths		Standardized*	Cumulative
Ν	% of all 4151 deaths	mortality rate	mortality
120	2.9 %	0.8	13

Second neoplasms (SN) within 20 yrs. of diagnosis (1980-2010): VIII (c) Ewing tumour and related sarcomas of bone

SN after VIII (c)			VIII (c) as SN aft	er any primary
	% of all	Cumulative		% of all	Cumulative
Ν	775 SN	incidence	Ν	775 SN	incidence
24	3.1 %	4.0 %	12	1.5 %	0.0 %

* Standard: Segi world standard population

Survival probabilities by year of diagnosis (Germany 1980-2009)

Age- and sex-specific incidence rates per million (Germany 2001-2010)

IX Soft tissue and other extraosseous sarcomas

(a) Rhabdomyosarcomas

(b) Fibrosarcomas, peripheral nerve sheath tumours and other fibrous neoplasms

(c) Kaposi sarcoma

(d) Other specified soft tissue sarcomas

Δ7

(e) Unspecified soft tissue sarcomas

Cases in Germany aged under 15 years (1980-2010): 2990

Selected characteristics (Germany 2001-2010)					
Relative frequency: 1064 / 17876 = 6.0 %					
Relative frequency of trial patients:95.7 %					
	<u></u>	_			
Incidence rates per million:	Girls	Boys	lotal		
Number of cases:	488	576	1064		
Standardized rate *:	8.7	10.0	9.4		
Cumulative incidence:	129	146	137		
Sex ratio (m/f): 1.2					

Age-specific incidence rates per million: 5-9 10-14 <1 1-4 Number of cases : 124 301 278

			_	
Incidence rate:	17.8	10.3	7.2	8.5
Median age at diagnosis:			6 years 9	months

	5-year	10-year	15-year
Survival probabilities:	73 %	70 %	68 %

Mortality per million within 10 yrs. of diagnosis (1991-2000):

N	umber of deaths	Standardized*	Cumulative
Ν	% of all 4151 deaths	mortality rate	mortality
376	9.1 %	3.0	43

Second neoplasms (SN) within 20 yrs. of diagnosis (1980-2010): IX Soft tissue and other extraosseous sarcomas

SN after IX IX as SN after any pri			any primary		
	% of all	Cumulative		% of all	Cumulative
Ν	775 SN	incidence	Ν	775 SN	incidence
52	6.7 %	3.0 %	52	6.7 %	0.2 %

* Standard: Segi world standard population

Survival probabilities by year of diagnosis (Germany 1980-2009)

Age- and sex-specific incidence rates per million (Germany 2001-2010)

361

Based on international comparisons, completeness of registration exceeds 95%. Compared to all childhood cancers, mortality is relatively high.

Cases in Germany aged under 15 years (1980-2010): 1734

Selected characteristics (Germany 2001-2010)				
Relative frequency: 572 / 17876 = 3.3 %				
Relative frequency of trial patients: 98.4 %				
Incidence rates per million:	Girls	Bovs	Total	
Number of cases:	259	313	572	
Standardized rate *:	4.8	5.6	5.2	
Cumulative incidence:	69	80	75	
Sex ratio (m/f): 1.2				

Age-specific incidence rates per million:

	<1	1-4	5-9	10-14
Number of cases :	47	229	173	123
Incidence rate:	6.7	7.9	4.5	2.9
Median age at diagnosis:			5 years 2	months

	5-year	10-year	15-yea
Survival probabilities:	73 %	71 %	70 %

Mortality per million within 10 yrs. of diagnosis (1991-2000):

N	umber of deaths	Standardized*	Cumulative
Ν	% of all 4151 deaths	mortality rate	mortality
231	5.6 %	1.9	27

Second neoplasms (SN) within 20 yrs. of diagnosis (1980-2010): IX (a) Rhabdomyosarcomas

SN af	iter IX (a)		IX (a) as SN after any primary		
	% of all	Cumulative		% of all	Cumulative
Ν	775 SN	incidence	Ν	775 SN	incidence
37	4.8 %	3.4 %	12	1.5 %	0.0 %

* Standard: Segi world standard population

Survival probabilities by year of diagnosis (Germany 1980-2009)

Age- and sex-specific incidence rates per million (Germany 2001-2010)

IX (b) Fibrosarcomas, peripheral nerve sheath tumours and other fibrous neoplasms

Based on international comparisons, completeness of registration exceeds 95%. These tumours are relatively frequent as second neoplasms.

Cases in Germany aged under 15 years (1980-2010): 265

Selected characteristics (Germany 2001-2010)

Relative frequency:	109 / 17876 = 0.6 %		
Relative frequency of trial patients:	87.2 %		
Incidence rates per million:	Girls	Boys	Total
Number of cases:	52	57	109
Standardized rate *:	0.9	1.0	1.0
Cumulative incidence:	14	14	14
Sex ratio (m/f):			1.1

Age-specific incidence rates per million:

	<1	1-4	5-9	10-14
Number of cases :	29	13	18	49
Incidence rate:	4.2	0.4	0.5	1.2
Median age at diagnosis:			8 years 6	months

	5-year	10-year	15-year
Survival probabilities:	68 %	64 %	61 %

Mortality per million within 10 yrs. of diagnosis (1991-2000):

N	lumber of deaths	Standardized*	Cumulative
Ν	% of all 4151 deaths	mortality rate	mortality
23	0.6 %	0.2	3

Second neoplasms (SN) within 20 yrs. of diagnosis (1980-2010): IX (b) Fibrosarcomas, peripheral nerve sheath tumours and other fibrous neoplasms

SN af	ter IX (b)		IX (b) as SN after any primary			
	% of all	Cumulative		% of all	Cumulative	
Ν	775 SN	incidence	Ν	775 SN	incidence	
4	0.5 %	2.4 %	14	1.8 %	0.1 %	

* Standard: Segi world standard population

Survival probabilities by year of diagnosis (Germany 1980-2009)

Age- and sex-specific incidence rates per million

(Germany 2001-2010)

Standardized* annual incidence rates per million (Germany 1980-2010)

Standardized* incidence rates per million by districts (Landkreise) (Germany 2001-2010)

50

Germany (2001-2010)	Ν	%
Fibrosarcomas, peripheral nerve sheath tumours and other	109	100.0
Fibroblastic and myofibroblastic tumours	62	56.9
Nerve sheath tumours	47	43.1
Other fibrous neoplasms	0	0.0

0.5

Fibroblastic and myofibroblastic tumour

Cases in Germany aged under 15 years (1980-2010): 129

Selected characteristics (Germany 2001-2010)

Relative frequency:		62 / 17876 = 0.3 %			
Relative frequency of trial pati	ents:			91.9 %	
Incidence rates per million:		Girls	Boys	Total	
Number of cases:		27	35	62	
Standardized rate *:		0.5	0.6	0.6	
Cumulative incidence:		7	9	8	
Sex ratio (m/f): 1.3				1.3	
Age-specific incidence rates per million:					
	<1	1-4	5-9	10-14	
Number of cases:	26	9	7	20	

Incidence rate: 3.7 0.3 0.2 Median age at diagnosis: 3 years 8 months

* Standard: Segi world standard population

Age- and sex-specific incidence rates per million (Germany 2001-2010)

2 Nerve sheath tumours

Cases in Germany aged under 15 years (1980-2010): 136

Selected characteristics (Germany 2001-2010)

Relative frequency:	47 / 17876 = 0.3 %		
Relative frequency of trial patients:			80.9 %
Incidence rates per million:	Girls	Boys	Total
Number of cases:	25	22	47
Standardized rate *:	0.4	0.4	0.4
Cumulative incidence:	6	5	6
Sex ratio (m/f):			0.9

Age-specific incidence rates per million:				
	<1	1-4	5-9	10-14
Number of cases:	3	4	11	29
Incidence rate:	0.4	0.1	0.3	0.7
Median age at diagnosis: 11 years 5 months				

* Standard: Segi world standard population

Age- and sex-specific incidence rates per million (Germany 2001-2010)

IX (d) Other specified soft tissue sarcomas

Based on international comparisons, completeness of registration approaches 95%. These tumours are relatively rarely followed by a second neoplasm (SN) within 20 years of diagnosis, underreporting of SN is a possibility.

Cases in Germany aged under 15 years (1980-2010): 802

Selected characteristics (Germany 2001-2010)				
Relative frequency:	302	2 / 17876	= 1.7 %	
Relative frequency of trial patients:			94.7 %	
	O iste	Davis	.	
incidence rates per million:	GINS	Boys	Iotai	
Number of cases:	137	165	302	
Standardized rate *:	2.3	2.7	2.5	
Cumulative incidence:	35	41	38	
Sex ratio (m/f): 1.2				

Age-specific incidence rates per million:

	<1	1-4	5-9	10-14
Number of cases :	37	45	69	151
Incidence rate:	5.3	1.5	1.8	3.6
Median age at diagnosis:		1	0 years 0	months

	5-year	10-year	15-yea
Survival probabilities:	75 %	70 %	67 %

Mortality per million within 10 yrs. of diagnosis (1991-2000):

N	lumber of deaths	Standardized*	Cumulative
Ν	% of all 4151 deaths	mortality rate	mortality
95	2.3 %	0.7	11

Second neoplasms (SN) within 20 yrs. of diagnosis (1980-2010): IX (d) Other specified soft tissue sarcomas

SN after IX (d)			IX (d)	as SN afte	er any primary
	% of all	Cumulative		% of all	Cumulative
Ν	775 SN	incidence	Ν	775 SN	incidence
9	1.2 %	1.8 %	23	3.0 %	0.1 %

* Standard: Segi world standard population

Survival probabilities by year of diagnosis (Germany 1980-2009)

Age- and sex-specific incidence rates per million

(Germany 2001-2010)

Standardized* incidence rates per million by districts (Landkreise) (Germany 2001-2010)

No map due to sparse data

51

52

X Germ cell tumours, trophoblastic tumours and neoplasms of gonads

- (a) Intracranial and intraspinal germ cell tumours
- (b) Malignant extracranial and extragonadal germ cell tumours
- (c) Malignant gonadal germ cell tumours

- (d) Gonadal carcinomas
- (e) Other and unspecified malignant gonadal tumours

Cases in Germany aged under 15 years (1980-2010): 1521

Selected characteristics (Germany 2001-2010)				
Relative frequency: 531 / 17876 = 3.0 %				
Relative frequency of trial patients: 97.2			97.2 %	
lu sidan sa ustas nau million.	Cirla	Dava	Tatal	
incidence rates per million:	GIRIS	Boys	Total	
Number of cases:	300	231	531	
Standardized rate *:	5.3	4.0	4.6	
Cumulative incidence:	79	58	68	
Sex ratio (m/f):			0.8	

Age-specific incidence rates per million:

	<1	1-4	5-9	10-14
Number of cases :	119	89	90	233
Incidence rate:	17.0	3.1	2.3	5.5
Median age at diagnosis:			9 years 0	months

	5-year	10-year	15-year
Survival probabilities:	95 %	94 %	93 %

Mortality per million within 10 yrs. of diagnosis (1991-2000):

N	lumber of deaths	Standardized*	Cumulative
Ν	% of all 4151 deaths	mortality rate	mortality
59	1.4 %	0.4	7

Second neoplasms (SN) within 20 yrs. of diagnosis (1980-2010): X Germ cell tumours, trophoblastic tumours and neoplasms of gonads

SN after X			Хa	s SN after	any primary
	% of all	Cumulative		% of all	Cumulative
Ν	775 SN	incidence	Ν	775 SN	incidence
14	1.8 %	1.6 %	6	0.8 %	0.0 %

* Standard: Segi world standard population

Survival probabilities by year of diagnosis (Germany 1980-2009)

Age- and sex-specific incidence rates per million (Germany 2001-2010)

X (a) Intracranial and intraspinal germ cell tumours

Most frequent form is germinoma (malignant). Non-malignant forms constitute about 10%, early childhood cases are rare, some underreporting is likely. These tumours are very rare as second neoplasms.

Cases in Germany aged under 15 years (1980-2010): 410

. .

Selected characteristics (Germany 200	J1-2010)		
Relative frequency:	156	6 / 17876 -	= 0.9 %
Relative frequency of trial patients:			95.5 %
		_	
Incidence rates per million:	Girls	Boys	Total
Number of cases:	61	95	156
Standardized rate *:	1.0	1.4	1.2
Cumulative incidence:	16	22	19
Sex ratio (m/f):			1.6

Age-specific incidence rates per million:

	<1	1-4	5-9	10-14
Number of cases :	4	7	47	98
Incidence rate:	0.6	0.2	1.2	2.3
Median age at diagnosis:			11 years	1 month

	5-year	10-year	15-year
Survival probabilities:	90 %	87 %	86 %

Mortality per million within 10 yrs. of diagnosis (1991-2000):

N	umber of deaths	Standardized*	Cumulative
Ν	% of all 4151 deaths	mortality rate	mortality
32	0.8 %	0.2	4

Second neoplasms (SN) within 20 yrs. of diagnosis (1980-2010): X (a) Intracranial and intraspinal germ cell tumours

SN after X (a)			X (a) as SN after any primary		
	% of all	Cumulative		% of all	Cumulative
Ν	775 SN	incidence	Ν	775 SN	incidence
5	0.6 %	2.0 %	1	0.1 %	0.0 %

* Standard: Segi world standard population

Survival probabilities by year of diagnosis (Germany 1980-2009)

Age- and sex-specific incidence rates per million

Standardized* incidence rates per million by districts (Landkreise) (Germany 2001-2010)

X (b) Malignant extracranial and extragonadal germ cell tumours

Based on international comparisons, completeness of registration exceeds 95%. These tumours are relatively rarely followed by a second neoplasm within 20 years of diagnosis. These tumours are very rare as second neoplasms.

Cases in Germany aged under 15 years (1980-2010): 444

Selected characteristics (Germany 2001-2010) Belative frequency: 146 / 17876 = 0.8 %

		,	
Relative frequency of trial patients:			96.6 %
Incidence rates per million:	Girls	Boys	Total
Number of cases:	95	51	146
Standardized rate *:	2.1	1.0	1.6
Cumulative incidence:	27	14	20
Sex ratio (m/f):			0.5

Age-specific incidence rates per million:

Survival probabilities:

	<1	1-4	5-9	10-14
Number of cases :	86	42	4	14
Incidence rate:	12.3	1.4	0.1	0.3
Median age at diagnosis:			0 years 9	months

5-year 10-year 15-year

96 %

95 %

95 %

Mortality per million within 10 yrs. of diagnosis (1991-2000):

N	lumber of deaths	Standardized*	Cumulative
Ν	% of all 4151 deaths	mortality rate	mortality
14	0.3 %	0.1	2

Second neoplasms (SN) within 20 yrs. of diagnosis (1980-2010): X (b) Malignant extracranial and extragonadal germ cell tumours

SN af	ter X (b)		X (b) as SN after any primary		
	% of all	Cumulative		% of all	Cumulative
Ν	775 SN	incidence	Ν	775 SN	incidence
4	0.5 %	1.5 %	1	0.1 %	0.0 %

* Standard: Segi world standard population

Survival probabilities by year of diagnosis (Germany 1980-2009)

Age- and sex-specific incidence rates per million (Germany 2001-2010)

Standardized* annual incidence rates per million (Germany 1980-2010)

Standardized* incidence rates per million by districts (Landkreise) (Germany 2001-2010)

No map due to sparse data

54

X (c) Malignant gonadal germ cell tumours

Girls are more and earlier affected than boys in puberty, boys are more likely to be affected in infancy. Age at diagnosis peaks at infancy and with puberty. Based on international comparisons, completeness of registration approaches 95%. These tumours are relatively rarely followed by a second neoplasm within 20 years of diagnosis. These tumours are rare as second neoplasms.

Cases in Germany aged under 15 years (1980-2010): 627

- - - -

Relative frequency: 224 / 17876 = 1.3 %				
Relative frequency of trial patients:			99.1 %	
Incidence rates per million:	Girls	Bovs	Total	
Number of cases:	139	85	224	
Standardized rate *:	2.1	1.6	1.9	
Cumulative incidence:	35	22	28	
Sex ratio (m/f): 0.6				

Age-specific incidence rates per million:

	<1	1-4	5-9	10-14
Number of cases :	29	40	38	117
Incidence rate:	4.2	1.4	1.0	2.8
Median age at diagnosis:		1	0 years 7	months

	5-year	TU-year	15-yea
Survival probabilities:	98 %	98 %	98 %

Mortality per million within 10 yrs. of diagnosis (1991-2000):

1	Number of deaths	Standardized*	Cumulative
Ν	% of all 4151 deaths	mortality rate	mortality
9	0.2 %	0.1	1

Second neoplasms (SN) within 20 yrs. of diagnosis (1980-2010): X (c) Malignant gonadal germ cell tumours

SN af	ter X (c)) X (c) as SN after any prima			r any primary
	% of all	Cumulative		% of all	Cumulative
Ν	775 SN	incidence	Ν	775 SN	incidence
5	0.6 %	1.5 %	4	0.5 %	0.0 %

* Standard: Segi world standard population

Survival probabilities by year of diagnosis (Germany 1980-2009)

Age- and sex-specific incidence rates per million (Germany 2001-2010)

Standardized* incidence rates per million by districts (Landkreise) (Germany 2001-2010)

56 XI (a) Adrenocortical carcinomas

Based on international comparisons, completeness of registration is by now close to 100%. The temporal trend is due to improvements in registration. These carcinomas are relatively frequently followed by a second neoplasm within 20 years of diagnosis. These carcinomas have so far not been reported as second neoplasms.

Cases in Germany aged under 15 years (1980-2010): 63

Selected characteristics (Germany 20	01-2010)			
Relative frequency: 29 / 17876 = 0.2 %				
Relative frequency of trial patients:		96.6 %		
Incidence rates per million:	Girls	Boys	Total	
Number of cases:	20	20,0	29	
Standardized rate *:	0.4	0.2	0.3	
	5	2.0	0.0	
Sov ratio (m/f):	5	2	0.5	
Sex ratio (m/r): 0.5				

Age-specific incidence rates per million:

	<1	1-4	5-9	10-14
Number of cases :	3	12	8	6
Incidence rate:	0.4	0.4	0.2	0.1
Median age at diagnosis:		3	years 11	months

	5-year	10-year	15-year
Survival probabilities:	-	-	-

Mortality per million within 10 yrs. of diagnosis (1991-2000):

١	lumber of deaths	Standardized*	Cumulative
Ν	% of all 4151 deaths	mortality rate	mortality
8	0.2 %	0.1	1

Second neoplasms (SN) within 20 yrs. of diagnosis (1980-2010): XI (a) Adrenocortical carcinomas

SN af	ter XI (a)		XI (a) as SN after any primary		
	% of all	Cumulative		% of all	Cumulative
Ν	775 SN	incidence	Ν	775 SN	incidence
4	0.5 %	8.0 %	0	0.0 %	0.0 %

* Standard: Segi world standard population

Survival probabilities by year of diagnosis (Germany 1980-2009)

Age- and sex-specific incidence rates per million (Germany 2001-2010)

Standardized* annual incidence rates per million (Germany 1980-2010)

Standardized* incidence rates per million by districts (Landkreise) (Germany 2001-2010)

XI (b) Thyroid carcinomas

Thyroid carcinomas are rare in early childhood. Based on international comparisons, completeness of registration approaches 95%. Thyroid carcinomas are relatively rarely followed by a subsequent neoplasm within 20 years of diagnosis, a large fraction of them are second neoplasms. Thyroid carcinoma is relatively frequent as a second neoplasm.

Cases in Germany aged under 15 years (1980-2010): 262

Selected characteristics (Germany 200	01-2010)				
Relative frequency: 131 / 17876 = 0.7 %					
Relative frequency of trial patients:			90.1 %		
		_	I		
Incidence rates per million:	Girls	Boys	Total		
Number of cases:	80	51	131		
Standardized rate *:	1.2	0.7	1.0		
Cumulative incidence:	20	12	16		
Sex ratio (m/f):			0.6		

Age-specific incidence rates per million:

	<1	1-4	5-9	10-14
Number of cases :	1	3	33	94
Incidence rate:	0.1	0.1	0.8	2.2
Median age at diagnosis:		1	2 years 6	months

	5-year	10-year	15-year
Survival probabilities:	96 %	92 %	87 %

Mortality per million within 10 yrs. of diagnosis (1991-2000):

1	Number of deaths	Standardized*	Cumulative
Ν	% of all 4151 deaths	mortality rate	mortality
6	0.1 %	0.0	1

Second neoplasms (SN) within 20 yrs. of diagnosis (1980-2010): XI (b) Thyroid carcinomas

SN af	ter XI (b)		XI (b) as SN after any primary		
	% of all	Cumulative		% of all	Cumulative
Ν	775 SN	incidence	Ν	775 SN	incidence
1	0.1 %	0.6 %	71	9.2 %	0.4 %

* Standard: Segi world standard population

Survival probabilities by year of diagnosis (Germany 1980-2009)

Age- and sex-specific incidence rates per million

(Germany 2001-2010)

Standardized* annual incidence rates per million (Germany 1980-2010)

Standardized* incidence rates per million by districts (Landkreise) (Germany 2001-2010)

- - -

Nasopharyngeal carcinomas are rare in early childhood. Based on international comparisons, completeness of registration is close to 100%. So far no second neoplasm after this carcinoma has been reported.

Cases in Germany aged under 15 years (1980-2010): 66

. .

Selected characteristics (Germany 20	01-2010)			
Relative frequency: 24 / 17876 = 0.1 %				
Relative frequency of trial patients: 100				
Incidence rotes nor million.	Girlo	Boyo	Total	
incidence rates per minion.	GINS	воуѕ	Total	
Number of cases:	6	18	24	
Standardized rate *:	0.1	0.2	0.2	
Cumulative incidence:	1	4	3	
Sex ratio (m/f):			3.0	

Age-specific incidence rates per million:

	<1	1-4	5-9	10-14
Number of cases :	0	1	0	23
Incidence rate:	0.0	0.0	0.0	0.5
Median age at diagnosis:		1	3 years 0	months

	5-year	10-year	15-year
Survival probabilities:	100 %	-	-

Mortality per million within 10 yrs. of diagnosis (1991-2000):

1	Number of deaths	Standardized*	Cumulative
Ν	% of all 4151 deaths	mortality rate	mortality
6	0.1 %	0.0	1

Second neoplasms (SN) within 20 yrs. of diagnosis (1980-2010): XI (c) Nasopharyngeal carcinomas

SN af	ter XI (c)		XI (c) as SN after any primary		
	% of all	Cumulative		% of all	Cumulative
Ν	775 SN	incidence	Ν	775 SN	incidence
0	0.0 %	0.0 %	3	0.4 %	0.0 %

* Standard: Segi world standard population

Survival probabilities by year of diagnosis (Germany 1980-2009)

Age- and sex-specific incidence rates per million (Germany 2001-2010)

Standardized* incidence rates per million by districts (Landkreise) (Germany 2001-2010)

No map due to sparse data

58

XI (d) Malignant melanomas

Early childhood cases of Malignant Melanoma (MM) are rare. Some underreporting is likely. The temporal trend is due to improvements in registration. So far no second neoplasm (SN) after MM has been reported, underreporting of SN is a possibility. Malignant melanoma is relatively frequent as a second neoplasm.

Cases in Germany aged under 15 years (1980-2010): 79

0040

Selected characteristics (definally 200	/1-2010)			
Relative frequency: 46 / 17876 = 0.3 %				
Relative frequency of trial patients:				
Incidence rates per million:	Girls	Boys	Total	
Number of cases:	23	23	46	
Standardized rate *:	0.4	0.4	0.4	
Cumulative incidence:	6	6	6	
Sex ratio (m/f): 1.0				

Age-specific incidence rates per million:

. .

	<1	1-4	5-9	10-14
Number of cases :	2	10	11	23
Incidence rate:	0.3	0.3	0.3	0.5
Median age at diagnosis:		9	years 11	months

	I.	1
5-year	10-year	15-yea

Survival probabilities: 82 % -

Mortality per million within 10 yrs. of diagnosis (1991-2000):

1	lumber of deaths	Standardized*	Cumulative
Ν	% of all 4151 deaths	mortality rate	mortality
11	0.3 %	0.1	1

Second neoplasms (SN) within 20 yrs. of diagnosis (1980-2010): XI (d) Malignant melanomas

SN after XI (d) XI (d) as SN after any prin			er any primary		
	% of all	Cumulative		% of all	Cumulative
Ν	775 SN	incidence	Ν	775 SN	incidence
0	0.0 %	0.0 %	16	2.1 %	0.1 %

* Standard: Segi world standard population

Survival probabilities by year of diagnosis (Germany 1980-2009)

Age- and sex-specific incidence rates per million (Germany 2001-2010)

Standardized* incidence rates per million by districts (Landkreise) (Germany 2001-2010)

No map due to sparse data

59

XII (a) Other specified malignant tumours

Most frequent form is pulmonary blastoma. Underreporting is likely. These carcinomas have so far not been reported as second neoplasms.

Cases in Germany aged under 15 years (1980-2010): 36

Selected characteristics (Germany 2001-2010) 15 / 17876 = 0.1 % **Relative frequency: Relative frequency of trial patients:** 80 % Incidence rates per million: Girls Boys Total 7 Number of cases: 8 15 Standardized rate *: 0.1 0.2 0.1 Cumulative incidence: 2 2 2 Sex ratio (m/f): 1.1

Age-specific incidence rates per million:

	<1	1-4	5-9	10-14
Number of cases :	0	9	2	4
Incidence rate:	0.0	0.3	0.1	0.1
Median age at diagnosis:			3 years 5	months

	5-year	10-year	15-year
Survival probabilities:	-	-	-

Mortality per million within 10 yrs. of diagnosis (1991-2000):

I	Number of deaths	Standardized*	Cumulative
Ν	% of all 4151 deaths	mortality rate	mortality
7	0.2 %	0.1	1

Second neoplasms (SN) within 20 yrs. of diagnosis (1980-2010): XII (a) Other specified malignant tumours

SN after XII (a)			XII (a) as SN after any primary		
	% of all	Cumulative		% of all	Cumulative
Ν	775 SN	incidence	Ν	775 SN	incidence
1	0.1 %	3.5 %	0	0.0 %	0.0 %

* Standard: Segi world standard population

Survival probabilities by year of diagnosis (Germany 1980-2009)

Age- and sex-specific incidence rates per million

(Germany 2001-2010)

Standardized* incidence rates per million by districts (Landkreise) (Germany 2001-2010)

No map due to sparse data

No figure due to sparse data